1. Home
  2. ANL vs IGR Comparison

ANL vs IGR Comparison

Compare ANL & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$9.36

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$4.62

Market Cap

719.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
IGR
Founded
2004
2004
Country
United States
United States
Employees
109
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
611.1M
719.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
ANL
IGR
Price
$9.36
$4.62
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
144.9K
508.2K
Earning Date
04-10-2026
01-01-0001
Dividend Yield
N/A
13.93%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.02
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$4.15
52 Week High
$17.25
$5.35

Technical Indicators

Market Signals
Indicator
ANL
IGR
Relative Strength Index (RSI) 40.75 53.23
Support Level $9.46 $4.46
Resistance Level $9.98 $4.86
Average True Range (ATR) 1.35 0.07
MACD 0.05 0.01
Stochastic Oscillator 27.46 65.52

Price Performance

Historical Comparison
ANL
IGR

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

Share on Social Networks: